Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study.

ABSTRACT:

Background

SARS-CoV-2 mRNA vaccines have proven high efficacy, however, limited data exists on the duration of immune responses and their relation to age and side effects.

Methods

We studied the antibody and memory T cell responses after the two-dose BNT162b2 vaccine in 122 volunteers up to 6 months and correlated the findings with age and side effects.

Findings

We found a robust antibody response to Spike protein after the second dose. However, the antibody levels declined at 12 weeks and 6 months post-vaccination, indicating a waning of the immune response over time. At 6 months after the second dose, the Spike antibody levels were similar to the levels in persons vaccinated with one dose or in COVID-19 convalescent individuals. The antibodies efficiently blocked AC

SUBMITTER: Naaber P 

PROVIDER: S-EPMC8418937 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature